Role of Pharmacodynamics in Antimicrobial Therapy G.L. Drusano, M.D. Director Institute for Therapeutic Innovation University of Florida
PK/PD PK/PD Effect Toxicity What Do We Want? (Maximize) (Minimize) Consequently, it is clear that there are two separate issues: PK/PD for effect (organism kill – clinical outcome/resistance suppression and PK/PD Optimal Patient for toxicity Outcome Obviously we wish to maximize effect and minimize toxicity The endpoint for toxicity is straightforward: the absence of an event The endpoint for effect is quite different – which endpoint is desired? 1. Clinical outcome 2. Microbiological outcome 3. Resistance suppression
Role of PK/PD • The Hierarchy of Endpoints (more therapeutic intensity required to achieve endpoint) 1. Clinical/Microbiological Outcome 2. Resistance Suppression • Let us first look at Microbiological Outcome (cell kill in animals) versus Resistance Suppression in an animal model system and, finally, (Micro Outcome) in a clinical trial
Role of PK/PD Inoculum of P. aeruginosa 10 6 Inoculum of P. aeruginosa 10 7 Non-Neutropenic Mouse Thigh Infection Model One needs more drug exposure to obtain a greater kill AND the bacterial burden is important! J Clin Invest 2003;112:275-285
Role of PK/PD • It is important to ask and answer the question of “Why does a minor increase in bacterial burden lead to such discordant drug intensities required for specific amounts of cell kill?”
Role of PK/PD Drusano GL. Nat Rev Microbiol 2004;2:289-300
Role of PK/PD Jumbe et al J Clin Invest 2003;112:275-285 Drusano GL. Nat Rev Microbiol 2004;2:289-300
Role of PK/PD AUC/MIC = 52 AUC/MIC = 157 J Clin Invest 2003;112:275-285
Role of PK/PD P. aeruginosa - Prevention of Amplification of Resistant Subpopulation • The amplification of the 10 7 ) U/ mL resistant sub-population is a 10 6 function of the AUC/MIC Re sista nt Muta nts (CF 10 5 ratio 10 4 • The response curve is an 10 3 inverted “U”. 100 • The AUC/MIC ratio for 10 resistant organism stasis is circa 185/1 0 50 100 150 200 250 Resistant organisms AUC 0-24 :MIC Ra tio at baseline All other data points represent resistant organism counts at 48 hours of therapy
Role of PK/PD • These data indicate that: 1. To kill more organisms, more drug exposure is required 2. To suppress resistance, more drug exposure is required than to kill wild-type cells * Can we identify relationships in the clinic?
Clinical PK/PD • Our group has identified the relationship between drug exposure and response, drug exposure and toxicity as well as (once) drug exposure and resistance suppression 15-20 times • We approach this in a standard fashion: 1. Identify a small number of blood sampling times using a Stochastic Optimal Design approach (D-optimality; determinant of the inverse Fisher Information Matrix) 2. Perform population PK modeling 3. Perform Bayesian estimation to obtain individual patient exposures to the drug; normalize to patient pathogen MIC 4. Linking exposure to response (logistic regression; time- to-event modeling)
Clinical PK/PD • Following, we will display data that were generated with a relatively small number of patients • The data were drawn from patients in a Phase III trial of Hospital-Acquired Bacterial Pneumonia • As above, we have done this many times for many drugs of different classes • We also have relationships for exposure-toxicity, so outcomes can be truly optimized
Clinical Trial of Levofloxacin 750 mg Daily for Patients with HAP Population pharmacokinetic parameter values derived from 58 Patients with Nosocomial Pneumonia Receiving 750 mg of Levofloxacin as a 1.5 Hour Constant Rate, Intravenous Infusion Vol Kcp Kpc CL hr -1 hr -1 Units L L/hr Means 34.4 7.65 6.07 7.24 Medians 23.3 2.66 0.924 6.24 S.D. 33.5 9.59 12.0 4.36 Vol = Volume of the central compartment; Kcp and Kpc are first order ntercompartmental transfer rate constants connecting the central and peripheral compartments; CL = Total clearance of Levofloxacin Drusano GL, SL Preston, C Fowler, M Corrado, B Weisinger, J Kahn J Infect Dis. 2004;189:1590-1597.
Final model for microbiological outcome for nosocomial pneumonia patients with receiving levofloxacin daily Final Model for Microbiological Outcome Constant Parameter Odds Ratio 95% Confidence Interval for Odds Ratio (AUC/MIC > 87) -2.197 1.374 3.952 11.596 – 1.347 (Age) 0.067 1.069 1.138 - 1.004 p = 0.001; McFadden’s ρ 2 = 0.31 Drusano GL, SL Preston, C Fowler, M Corrado, B Weisinger, J Kahn J Infect Dis. 2004;189:1590-1597.
Role of PK/ PD L e vo flo xac in and Ho spital-Ac quir e d Pne umo nia siste nc e 1.0 AUC:MIC Ra tio ≥ 87 AUC:MIC Ra tio < 87 0.8 obability of Pe r 0.6 0.4 0.2 0.0 Pr 20 40 60 80 100 120 Age (ye ar s) Drusano GL, SL Preston, C Fowler, M Corrado, B Weisinger, J Kahn J Infect Dis. 2004;189:1590-1597.
Role of PK/ PD L e vo flo xac in and Ho spital-Ac quir e d Pne umo nia • So, the exposure target (AUC/MIC ratio) that mediates a 2 log 10 CFU/g drop in the mouse is identified as the exposure needed to drive a high probability of a good microbiological outcome in patients with nosocomial pneumonia • How often does a fixed dose of drug achieve this target? • We will examine this with Monte Carlo Simulation
E VAL UAT ING DOSE S Use of Monte Ca rlo Simula tion Drusano GL, SL Preston, C Fowler, M Corrado, B Weisinger, J Kahn J Infect Dis. 2004;189:1590-1597.
Table 6. Target-attainment rates for a 750 mg intravenous dose of levofloxacin, for distributions of Pseudomonas aeruginosa (n = 404) and Enterobacter cloacae (n = 297) isolates, by use of a 10,000 subject Monte Carlo simulation. _______________________________________________ AUC:MIC ratio P. aeruginosa , % E. cloacae , % Breakpoint _______________________________________________ 87.0 72.4 91.7 Drusano GL, SL Preston, C Fowler, M Corrado, B Weisinger, J Kahn J Infect Dis. 2004;189:1590-1597.
PK -PD o f Antib a c te ria l Ag e nts Right Cho ic e , Right T ime , Right Do se • So, Levofloxacin 750 mg daily is an “ adequate ” dose for E. cloacae (circa 92% target attainment), but is inadequate as a single agent for P. aeruginosa (72%) • The pharmacodynamics lessons learned from in vivo and in vitro models DO bridge to man • We CAN perform smaller, focused trials using a pharmacodynamic approach that teach us how to use these agents optimally • What about resistance suppression? We have the data, but not the time. For those interested, please chat with me at the break
Thank You for Your Attention!
Resistance suppression • We cannot use the levo HAP trial to evaluate resistance suppression, as, when P. aeruginosa was isolated, a second drug was added – BUT the Fink trial with ciprofloxacin (400 mg IV Q8 h) and the Peloquin Cipro trial (200 IV Q12h) were single agent trials
PK -PD T ART GE T AT T AI NME NT Cipr o flo xac in Against P. ae r ugino sa lo Simulatio n Use o f Mo nte Car Taking the expectation demonstrates an overall target attainment of 62% and a predicted emergence of resistance rate of 38% for 400 Q8h. For 200 Q12h, the expected results would be 25% target attainment and 75% resistance emergence
MONT E CARL O SI MUAT I ON e dic tive ? Is It Pr • Peloquin studied 200 mg IV Q 12 h of ciprofloxacin in nosocomial pneumonia - P aeruginosa resistance rate 70% (7/10 - pneumonia only) - 77% (10/13 - Pneumonia plus bronchiectasis  plus empyema ) • MCS (resistance suppression target) predicts emergence of resistance in 75% • Fink et al studied ciprofloxacin in nosocomial pneumonia (400 mg IV Q 8 h) - P aeruginosa resistance rate 33% (12/36) • MCS at this dose and schedule predicts suppression in 62% and emergence of resistance in 38% Peloquin et al Arch Int Med 1989;1492269-73 Fink et al AAC 1994;38:547-57
Role of PK- PD L e sso ns L e ar ne d • We have shown that the cell kill in the animal model of 2 logs is associated with an AUC/MIC ratio of 88; a ratio of 87 was demonstrated in a clinical trial to be linked to good microbiological outcome • In vitro (not shown) and animal models demonstrated the ability to choose a dose to suppress resistance • These predictions are validated in two different clinical trials with two different doses and schedules • We have shown in an in vitro model that Resistance Suppression Requires More Drug Exposure than Cell Kill!
9/21/2017 Antimicrobial Stewardship JONATHAN PERDUE, PHARMD PGY1 PHARMACY RESIDENT ST. CLAIRE REGIONAL MEDICAL CENTER 09/23/2017 1 Disclosure This speaker has no actual or potential conflicts of interest related to this presentation 2
189 views • 17 slides
IFF TO COMBINE WITH DUPONT NUTRITION & BIOSCIENCES Creates New Global Integrated Solutions Leader December 16, 2019 CAUTIONARY STATEMENT Cautionary Note on Forward-Looking Statements This communication contains forward - looking
791 views • 25 slides
Chemoinformatics decision support for antimicrobial pesticides Also known as the project to develop a thresholds of toxicological concern framework for antimicrobial pesticides decision support 1 Basic overarching question: How can we use
617 views • 38 slides
Pioneering development in novel antibiotics and immuno-oncology Disclaimer This presentation (the Presentation) has been prepared by Polyphor Ltd. (the Company and together with its subsidiary, we, us or the Group)
1.02k views • 27 slides
Georgetown Infectious Disease Atlas (GIDA): Tracking funding for Global Health Security Dr. Ellie Graeden, Talus Analytics Funding for global health security Significant funding increase for global health security with the launch of GHSA in
887 views • 39 slides
Healthcare Associated Infection(HAI) Prevention Healthcare Associated Infections (HAI) One in every 25 hospital patients has at least one HAI HAI incidences raise patient healthcare costs and time HAI can cause death to affected patients HAI
646 views • 30 slides
Whats In Store Fall 2010 resolve cases involving unsubstantiated Is Your Pillow a Pesticide? The EPA antimicrobial claims. Califone International, Inc., Steps Up Enforcement of Antimicrobial which claimed that its headphones prevented
279 views • 7 slides
Antimicrobial Stewardship Messaging in Canada Changing Attitudes and Behaviours to Drive Change Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria July 11, 2019 Denise Gilby, M.Sc. Public Health Agency of Canada Key
370 views • 14 slides
Dutch antibiotic resistance policy A One Health Approach Ministry of Health, Welfare and Sport Ministry of Economic Affairs Ministry of Infrastructure and the Environment AMR Media Seminar 16 11- 2015 Background (1) Doing
737 views • 17 slides
ANT I MI CROBI AL ST E WARDSHI P AND ANT I BI OGRAM Jo se ph P. I se r, MD, DrPH, MSc Chie f He a lth Offic e r, So uthe rn Ne va da He a lth Distric t CDC AND WI NNABL E BAT T L E S T o b a c c o Mo to r Ve hic le
501 views • 12 slides
The Nuts and Bolts of Antibiograms in Long-Term Care Facilities J. Kristie Johnson, Ph.D., D(ABMM) Professor, Department of Pathology University of Maryland School of Medicine Director, Microbiology Laboratories University of Maryland Medical
824 views • 41 slides
Antimicrobial resistance: the view of the EGGVP London, 15 September 2011 Key actors Vets Farmers, animal keepers Distributors Industry Competent authorities / Regulators Responsible use is the key step to fight against resistance Key
510 views • 13 slides
Preventing and treating chronic infections SoftOx Solutions AS A Norwegian MedTech Company listed on Merkur, OSE Agenda Introduction 4th Quarter 2019 Key highlights Key Figures The challenge Highlights The SoftOx
866 views • 19 slides
Antimicrobial Stewardship: Response to a Global Crisis Carla Walraven, PharmD, BCPS-AQ ID University of New Mexico Hospital Antimicrobial Stewardship Program Pharmacist Objectives Explain the implications of antimicrobial resistance
650 views • 48 slides
Antibiotic stewardship and the role of improved diagnosis in the management of acute respiratory tract infections Matthew Thompson, MD, MPH, PhD University of Washington Department of Family Medicine Objectives Discuss antimicrobial
664 views • 42 slides
Development and evaluation of a complex ePrescribing-based Antimicrobial Stewardship (ePAMS+) intervention for hospitals. NIHR Programme Grant for Applied Research Overview Previous NIHR grant Research into implementation and effectiveness
455 views • 26 slides
Antimicrobial Resistance: A global public health threat Dr Mark Schipp Australian Chief Veterinary Officer Rotary WA May 2019 1 A very quick introduction What is AMR? - When micro-organisms evolve resistance to antimicrobial substances,
681 views • 14 slides
COVID-19 HCPF Office of Community Living Presented by: Kim Bimestefer, Julie Reiskin, Dr. Tracy Johnson, Dr. Lisa Latts, and Bonnie S ilva March 20, 2020 1 Overview High-level overview of Department actions Kim Bimestefer, HCPF
688 views • 23 slides
ANTIMICROBIAL THERAPY FOR UNCOMPLICATED CYSTITIS IN THE EMERGENCY DEPARTMENT Jamie L. Voigtmann PharmD Christian Hospital PGY1 Pharmacy Resident Residency Director - Jackie Harris PharmD, BCPS Project Mentor - Jessica Kolkmeyer PharmD,
458 views • 28 slides
1 Bactiguard Q2 presentation August 10, 2017 2 Infections and antimicrobial resistance Increasing media and public attention Antimicrobial resistance is one of the greatest challenges of our time, as it threatens healthcare, the world
682 views • 22 slides
Graphical Presentation of Antimicrobial Activity ANTIBACTERIAL ACTIVITY Antibacterial activity: Standard drugs 246 Graphical Presentation of Antimicrobial Activity 247 Graphical Presentation of Antimicrobial Activity 248 Graphical
447 views • 6 slides
Fighting Infections and Antimicrobial Resistance Through GPU-Accelerated In Silico Models Radu Marculescu Carnegie Mellon University GTC, April 5, 2016 Bacteria are among the earliest forms of life that appeared on Earth billions of years ago.
432 views • 18 slides
Presentation Guide Simple Steps o Understand your product o What problem is being solved? o Who is the target market? o Who/What is the competition? o What is the competitive advantage? o Understand and build financials Common Bad Dental Behavior
450 views • 12 slides
The new EC action plan against antimicrobial resistance ngela Bolufer de Gea AMR Task Force Directorate General for Health and Food Safety AMR and Workplace learning: the case for a multi-professional approach in hospitals 22 Nov 2017,
291 views • 10 slides